Please login to the form below

Not currently logged in
Email:
Password:

cancer

This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Our goal is to provide cancer patients with medicines that have the potential to extend their lives, ”said Johanna Mercier, BMS’head of US commercial. ... Roche has also reported Sutent-topping results with it’s combination of PD-L1 inhibitor

Latest news

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    AZ makes case for first-line Tagrisso therapy in lung cancer. Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva. ... using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung cancer (NSCLC).

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    Merck’ s Keytruda scores in frontline lung cancer yet again. Drug improved overall survival as a monotherapy, which rival BMS’Opdivo was unable to show. ... used in more than two thirds of all patients presenting with this common form of cancer.

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... a form of skin cancer, but was unable to show any improvement over Keytruda alone on progression-free

  • Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

    Reviews start for Pfizer’ s wildcard lung cancer drug dacomitinib. Both EU and US regulatory advisors are currently assessing the drug. ... Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... Sanofi has filed cemiplimab in the first instance as a treatment for advanced cutaneous squamous cell carcinoma (CSCC),

More from news
Approximately 620 fully matching, plus 1,420 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on

  • Beyond caring: learning from the unsung advocates in cancer care

    Inequalities in care threaten to extinguish hope. Inequalities are sadly common in cancer care. ... Given their tenacity, strength and knowledge honed through their determination, isn’t it time that we did more for advocates in cancer?

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    Unlike cancer or other diseases where there are often a multitude of causative factors, cystic fibrosis is caused by.

  • Health on instalment Health on instalment

    years. Initial disease targets include cancer, neuromuscular disease, haemophilia, immunodeficiencies and blindness. ... Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively.

  • The rise of real-world evidence The rise of real-world evidence

    The evidence has applications in multiple therapeutic areas. Roche showed the value it places on real-world cancer evidence when it struck a $1.9bn (£1.3bn) deal to acquire oncology ... The takeover was driven by a belief that “regulatory-grade

More from intelligence
Approximately 5 fully matching, plus 224 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 193 partially matching documents found.

Latest from PMHub

  • Why is the UK lagging behind the rest of Europe in cancer survival?

    Catch the cancer. Ready. Steady. Go. Another  study found tumour DNA in blood samples of over 80% of those with advanced cancers and nearly 50% with localised and early stage cancers. ... researcher called  Dennis Lo, who is close to perfecting the

  • Patient Perspective - Rectal Cancer - The Diagnosis

    Patient Perspective - Rectal Cancer - The Diagnosis. At Synergy Vision, we aim to make a difference to patients. ... In the third video in our patient perspective series we are talking about the diagnosis of rectal cancer.

  • Bowel Cancer Awareness Month

    Bowel cancer is one of most common cancers diagnosed in the UK, but with early diagnosis and treatment, most cases can be treated successfully. ... To raise awareness, we’ ve created this infographic with some facts on bowel cancer in the UK.

  • Hayward Medical Communications continues partnership with Prostate Cancer UK

    Hayward Medical Communications continues partnership with Prostate Cancer UK. Long-standing relationship creates new ventures. ... Most recently, Hayward and Prostate Cancer UK have begun a new project to further improve the patient journey.

  • The role of pharma in cancer survivorship

    care. World Cancer Day 2017 marks the second year of a three-year project. ... This was initially developed by the National Cancer Survivorship initiative in 2008 by the Department of Health and Macmillan Cancer Support.

More from PMHub
Approximately 31 fully matching, plus 151 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics